UnknownNCT03642964
A Study in Patients With Major Depressive Disorder
Medication studyAges 18–65United StatesDepression
Understand this study
Who could participate?
This study is for people with depression. Listed age limits: 18 years to 65 years. Other eligibility criteria apply.
- Listed locations
- Long BeachSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: September 10, 2018
- Recruitment status
- Unknown
- Enrollment listed in the registry
- 24
- Sponsor
- Chase Therapeutics Corporation
- Sponsor type
- Biotech company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT03642964
- Official title
Show the full official title
A Phase 2a Study to Evaluate the Safety, Tolerability and Initial Efficacy of Pramipexole IR, Given With Ondansetron in Patients With Major Depressive Disorder
Recruitment & locations
Status unknownLong Beach
A listed location does not confirm current availability.
Questions about this study
Who is behind this study?
The study sponsor is Chase Therapeutics Corporation.
Does this study involve medication?
Yes. The study involves medication, including CTC-501.
Who can participate?
This study is for people with depression. Listed age limits: 18 years to 65 years. Other eligibility criteria apply.
